PepGen (PEPG) Enterprise Value (2021 - 2026)
PepGen (PEPG) posted Enterprise Value of -$132.3 million for Q1 2026, up 10.88% sequentially from -$148.5 million in Q4 2025, and down 35.31% YoY from -$204.5 million in Q1 2025.
PepGen (PEPG) Enterprise Value (2021 - 2026) Analysis & Trends
PepGen has reported Enterprise Value for 6 years, with the latest figure at -$132.3 million in Q1 2026.
- Quarterly Enterprise Value fell 35.31% year-over-year to -$132.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$132.3 million (down 35.31% YoY) and the FY2025 annual result came in at -$148.5 million, down 23.52% from the prior year.
- Enterprise Value advanced to -$132.3 million in Q1 2026 per PEPG's latest filing, from -$148.5 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$74.7 million in Q2 2025 and troughed at -$218.8 million in Q2 2022.
- A 5-year average of -$145.9 million and a median of -$147.0 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value slumped 1682.72% in 2022, then soared 53.72% in 2025.
- Over 5 years, Enterprise Value stood at -$181.8 million in 2022, then surged by 39.25% to -$110.4 million in 2023, then retreated by 8.86% to -$120.2 million in 2024, then fell by 23.52% to -$148.5 million in 2025, then increased by 10.88% to -$132.3 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$132.3 million, -$148.5 million, and -$163.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | PepGen | 207.09 Mn | 207.09 Mn | - | -117.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -117.24 Mn |
| Mar 31, 2026 | -132.30 Mn |
| Dec 31, 2025 | -148.46 Mn |
| Sep 30, 2025 | -163.67 Mn |
| Jun 30, 2025 | -74.65 Mn |
| Mar 31, 2025 | -97.78 Mn |
| Dec 31, 2024 | -120.19 Mn |
| Sep 30, 2024 | -138.86 Mn |
| Jun 30, 2024 | -161.31 Mn |
| Mar 31, 2024 | -175.22 Mn |
| Dec 31, 2023 | -110.41 Mn |
| Sep 30, 2023 | -129.54 Mn |
| Jun 30, 2023 | -147.03 Mn |
| Mar 31, 2023 | -165.40 Mn |
| Dec 31, 2022 | -181.75 Mn |
| Sep 30, 2022 | -195.78 Mn |
| Jun 30, 2022 | -218.82 Mn |
| Mar 31, 2022 | -118.85 Mn |
| Dec 31, 2021 | -132.90 Mn |
| Sep 30, 2021 | -141.54 Mn |